Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports
Abstract Background Renal cell carcinoma represents 3–5% of adult malignant tumors. Metastases are found in 30–40% of patients and brain metastases occurred in more than 10% of them. Despite significant progress in medical treatment, patients with brain metastases still have a limited survival. Cabo...
Main Authors: | Sylvie Négrier, Guillaume Moriceau, Valéry Attignon, Véronique Haddad, Daniel Pissaloux, Nicole Guerin, Christian Carrie |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13256-018-1875-9 |
Similar Items
-
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
by: Jeffrey Sum-Lung Wong, et al.
Published: (2021-04-01) -
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
by: Francesco Tovoli, et al.
Published: (2021-06-01) -
Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
by: Debaillon Vesque A, et al.
Published: (2020-06-01) -
Atypical Posterior Reversible Encephalopathy Syndrome due to Oral Tyrosine Kinase Inhibitor Cabozantinib: First Case Report
by: Anannya Patwari, et al.
Published: (2020-08-01) -
Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma
by: Gerendash BS, et al.
Published: (2017-10-01)